Literature DB >> 9699889

Restenosis in human vein bypass grafts.

S Nikol1, T Y Huehns, L Weir, T N Wight, B Höfling.   

Abstract

The restenosis rate in vein bypass grafts is higher than in native coronary arteries, and both the cascade of regulatory factors and the vessel reaction may be altered. In this study, vein bypass atherectomy specimens were classified as primary (n = 10) or restenotic (n = 12). Immunohistochemistry with 11 primary antibodies showed low levels of proliferation in both tissues and similar amounts of extracellular matrix components in both primary and restenotic specimens at the time points at which tissue was removed for clinical reasons. Inflammation appeared increased in restenotic specimens. Using in situ hybridization, transforming growth factor-beta1 messenger RNA was detected in both primary and restenotic tissue, with a trend to higher expression in restenosis (8.4 +/- 5.3 vs. 9.4 +/- 7.4 grains/nucleus) and further increased expression in multiple compared with single restenoses (15.1 +/- 6.1 vs. 5.6 +/- 5.1 grains/nucleus, P < 0.05). Hence, there were no great differences in cell proliferation or extracellular matrix formation between primary and restenosis vein graft tissue, in contrast to previously described findings in arterial tissue. This suggests that primary vein graft tissue is already in a chronic 'restenosis-like' state and subsequent injury creates minimal additional upregulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699889     DOI: 10.1016/s0021-9150(98)00050-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  1 in total

1.  Intimal hyperplasia following implantation of helical-centreline and straight-centreline stents in common carotid arteries in healthy pigs: influence of intraluminal flow.

Authors:  Colin Gerald Caro; Anusha Seneviratne; Kevin B Heraty; Claudia Monaco; Martin G Burke; Rob Krams; Carlos C Chang; Paul Gilson; Gianfilippo Coppola
Journal:  J R Soc Interface       Date:  2013-10-16       Impact factor: 4.118

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.